PURPOSE：ThisphaseⅡtrialwasdesignedtodefinetheroleofO^6-benzylguanine（O^6-BG）inrestoringtemozolomidesensitivityinpatientswithrecurrentorprogressive,temozolomidc-resistantmalignantgliomaandtoevaluatethesafetyofadministeringO^6-BGincombinationwithtemozolomide.PATIENTSANDMETHODS：Patientswereaccruedintotwoindependentstrataonthebasisofhistology：glioblastomamultifonne（GBM）andaanaplasticglioma.BothtemozolomideandO6-BGwereadministeredonday1ofa28-daytreatmentcycle.Patientswereadministereda1-hourO^6-BGinfusionatadoseof120mg/m^2followedimmediatelybya48-hourinfusionatadoseof30mg/m^2/d.
